Arkolith/Insider Trading/KROS/Form 4/A

Cho Esther

Chief Legal OfficerKeros Therapeutics, Inc. (KROS) · full profile →Form 4/A · filed Mar 27, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 24, 2026Grant(A)80K—$080K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0002081460-26-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML